| Angiogenesis: regulators and clinical applications S Liekens, E De Clercq, J Neyts Biochemical pharmacology 61 (3), 253-270, 2001 | 1189 | 2001 |
| N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 M McCallum, A De Marco, FA Lempp, MA Tortorici, D Pinto, AC Walls, ... Cell 184 (9), 2332-2347. e16, 2021 | 934 | 2021 |
| Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture AH De Wilde, D Jochmans, CC Posthuma, JC Zevenhoven-Dobbe, ... Antimicrobial agents and chemotherapy 58 (8), 4875-4884, 2014 | 918 | 2014 |
| Animal models for COVID-19 C Muñoz-Fontela, WE Dowling, SGP Funnell, PS Gsell, AX Riveros-Balta, ... Nature 586 (7830), 509-515, 2020 | 882 | 2020 |
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine E Keyaerts, L Vijgen, P Maes, J Neyts, M Van Ranst Biochemical and biophysical research communications 323 (1), 264-268, 2004 | 862 | 2004 |
| α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment L Zhang, D Lin, Y Kusov, Y Nian, Q Ma, J Wang, A Von Brunn, P Leyssen, ... Journal of medicinal chemistry 63 (9), 4562-4578, 2020 | 609 | 2020 |
| Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches M Guilliams, J Bonnardel, B Haest, B Vanderborght, C Wagner, ... Cell 185 (2), 379-396. e38, 2022 | 599 | 2022 |
| Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms MA Tortorici, M Beltramello, FA Lempp, D Pinto, HV Dang, LE Rosen, ... Science 370 (6519), 950-957, 2020 | 549 | 2020 |
| An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge G Yang, DC Pevear, MH Davies, MS Collett, T Bailey, S Rippen, L Barone, ... Journal of virology 79 (20), 13139-13149, 2005 | 508 | 2005 |
| Favipiravir as a potential countermeasure against neglected and emerging RNA viruses L Delang, R Abdelnabi, J Neyts Antiviral research 153, 85-94, 2018 | 496 | 2018 |
| Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug E Mastrangelo, M Pezzullo, T De Burghgraeve, S Kaptein, B Pastorino, ... Journal of Antimicrobial Chemotherapy 67 (8), 1884-1894, 2012 | 482 | 2012 |
| Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern L Vangeel, W Chiu, S De Jonghe, P Maes, B Slechten, J Raymenants, ... Antiviral research 198, 105252, 2022 | 459 | 2022 |
| SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape TN Starr, N Czudnochowski, Z Liu, F Zatta, YJ Park, A Addetia, D Pinto, ... Nature 597 (7874), 97-102, 2021 | 458 | 2021 |
| Structure and functionality in flavivirus NS-proteins: perspectives for drug design M Bollati, K Alvarez, R Assenberg, C Baronti, B Canard, S Cook, ... Antiviral research 87 (2), 125-148, 2010 | 453 | 2010 |
| The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine) n-specific plant lectin from Urtica dioica are potent and … J Balzarini, J Neyts, D Schols, M Hosoya, E Van Damme, W Peumans, ... Antiviral research 18 (2), 191-207, 1992 | 360 | 1992 |
| The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase P Leyssen, J Balzarini, E De Clercq, J Neyts Journal of virology 79 (3), 1943-1947, 2005 | 351 | 2005 |
| The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro J Paeshuyse, A Kaul, E De Clercq, B Rosenwirth, JM Dumont, P Scalfaro, ... Hepatology 43 (4), 761-770, 2006 | 350 | 2006 |
| Broad betacoronavirus neutralization by a stem helix–specific human antibody D Pinto, MM Sauer, N Czudnochowski, JS Low, MA Tortorici, MP Housley, ... Science 373 (6559), 1109-1116, 2021 | 344 | 2021 |
| Perspectives for the Treatment of Infections withFlaviviridae P Leyssen, E De Clercq, J Neyts Clinical microbiology reviews 13 (1), 67-82, 2000 | 335 | 2000 |
| HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections L Naesens, R Snoeck, G Andrei, J Balzarini, J Neyts, E De Clercq Antiviral Chemistry and Chemotherapy 8 (1), 1-23, 1997 | 325 | 1997 |
